Core Viewpoint - The incident involving Beijing Tongrentang's Antarctic krill oil product has raised significant concerns about false advertising and quality control in the health supplement industry, leading to the product's removal from major e-commerce platforms [1][2][4]. Group 1: Product and Market Analysis - The product in question, marketed as "99% high purity Antarctic krill oil," was found to contain no actual krill oil, despite claims of 43% phospholipid content [4][7]. - The product was sold at a price of approximately 60 yuan per bottle, while the production cost was only between 3 to 3.7 yuan [7][9]. - The product's packaging prominently featured the "Beijing Tongrentang" name, which misled consumers regarding its authenticity and quality [4][11]. Group 2: Regulatory and Consumer Protection - The Shanghai Consumer Protection Committee conducted an industry evaluation that led to the discovery of the misleading claims and initiated a formal inquiry with the involved parties [4][7]. - The committee questioned the accountability of the distributor, Sichuan Health Pharmaceutical, which denied knowledge of the fraudulent practices, raising concerns about the integrity of the supply chain [7][11]. - The committee emphasized the need for better consumer protection and accountability in the health food sector, particularly regarding the marketing of functional foods [9][11]. Group 3: Brand Reputation and Industry Implications - The incident has put the reputation of the Tongrentang brand at risk, highlighting issues related to brand management and oversight of sub-brands [2][13]. - There is a growing concern about the prevalence of counterfeit and misleading products associated with the Tongrentang name, which could further damage consumer trust [15]. - This is not the first quality crisis for Tongrentang, as previous incidents have also raised questions about the company's quality control and brand management practices [15].

Core Viewpoint - The incident involving Beijing Tongrentang's Antarctic krill oil product highlights significant issues in the health supplement industry, particularly regarding false advertising and brand management failures [2][9]. Group 1: Product Misrepresentation - A product marketed as "99% high purity Antarctic krill oil" was found to contain no actual krill oil, despite claims of 43% phospholipid content [3][6]. - The product was sold at approximately 60 yuan per bottle, while the production cost was only between 3 to 3.7 yuan, indicating a substantial markup [6][8]. - The packaging prominently featured "Beijing Tongrentang," misleading consumers about the product's authenticity and quality [3][10]. Group 2: Regulatory Response - The Shanghai Consumer Protection Commission conducted an industry evaluation that led to the product's withdrawal from major e-commerce platforms following the detection of misleading claims [1][6]. - During an inquiry, the manufacturer admitted to not including the advertised krill oil in the product, while the distributor denied any knowledge of the fraudulent practices [6][8]. - The commission raised questions about the accountability of the involved parties, emphasizing the need for transparency in the supply chain [7][8]. Group 3: Brand Reputation and Industry Implications - The incident has drawn public attention to the broader issues of brand management and quality control within the health supplement sector, particularly for established brands like Tongrentang [2][9]. - The company has distanced itself from the implicated entities, clarifying that the distributor is not a direct subsidiary, although both are part of the same corporate group [10]. - Previous quality issues faced by Tongrentang, including a 2018 incident involving expired honey, have compounded concerns about the brand's integrity and oversight [11].

记者丨闫硕 编辑丨季媛媛 视频丨柳润瑛 见习记者陈泽锴 一款南极磷虾油引发的造假风波，再次将同仁堂贴牌乱象推向台前。 近日，上海市消保委对市面上热销的15款国内外南极磷虾油产品开展了检测和调查，其中一款标称"北京同仁堂99%高纯南极磷虾油"的产品，磷 脂含量为0，涉嫌造假。 这款涉事产品并非北京同仁堂直接生产，而是由其孙公司北京同仁堂（四川）健康药业有限公司（简称"四川健康药业"）负责经销，实际生产 代工方为安徽哈博药业有限公司（简称"哈博药业"），属于典型的贴牌模式。 12月15日下午，上海市消保委正式约谈了该产品的经销商与生产商，哈博药业承认在生产过程中未添加其对外宣称的"南极磷虾油"；产品包装 按照四川健康药业要求制作。 与此同时，同仁堂健康会员微信公众号发布声明：这款产品未经授权擅自突出使用"北京同仁堂"字样，涉嫌违法，公司已启动司法程序，对涉 事企业进行起诉。目前，四川健康药业已停止经销该产品。 北京同仁堂是"同仁堂"商标唯一合法持有人，其起源可追溯至1669年，凭借数百年的品牌积淀成为中药行业老字号标杆。但近年来，北京同仁 堂多次因贴牌乱象陷入信任危机。有业内观点认为，其在品牌授权管理、子公司管控 ...

记者丨 闫硕 编辑丨季媛媛 视频丨柳润瑛 见习记者陈泽锴 一款南极磷虾油引发的造假风波，再次将同仁堂贴牌乱象推向台前。 近日，上海市消保委对市面上热销的15款国内外南极磷虾油产品开展了检测和调查，其中 一款标称"北京同仁堂99%高纯南极磷虾 油"的产品，磷脂含量为0，涉嫌造假。 这款涉事产品并非北京同仁堂直接生产，而是由其孙公司北京同仁堂（四川）健康药业有限公司（简称"四川健康药业"）负责经销， 实际生产代工方为安徽哈博药业有限公司（简称"哈博药业"），属于典型的贴牌模式。 12月15日下午，上海市消保委正式约谈了该产品的经销商与生产商， 哈博药业承认在生产过程中未添加其对外宣称的"南极磷虾油"； 产品包装按照四川健康药业要求制作 。 北京同仁堂陷信任危机 南极磷虾油在调节代谢与心血管保护、骨骼健康维护、神经保护与认知等方面有一定功效。 最近，南极磷虾油成为健康圈的"香饽 饽"，但市面上南极磷虾油品牌繁多，价格差距悬殊，品质更是难以辨别 。 与此同时，同仁堂健康会员微信公众号发布声明：这款产品未经授权擅自突出使用"北京同仁堂"字样，涉嫌违法，公司已启动司法程 序，对涉事企业进行起诉。目前，四川健康药业已停止经 ...